Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

1130

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
CRC
Pancreatic Ductal Adenocarcinoma
PDAC
Gastrointestinal Cancer
Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: RMC-6236
DRUG: mFOLFOX6 regimen
DRUG: bevacizumab
DRUG: mFOLFIRINOX regimen
DRUG: cetuximab
DRUG: gemcitabine
DRUG: nab-paclitaxel
DRUG: RMC-9805

Sponsor

Revolution Medicines, Inc.